Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults
Launched by NOVARTIS VACCINES · Feb 12, 2008
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy
- • Ages 18-40
- • Negative for H. pylori infection
- • Contraception for females
- Exclusion Criteria:
- • Present or past H. pylori infection
- • Medically significant gastroduodenal disease
- • Recent corticosteroid use
- • Bleed diathesis
- • Use of antibiotics used to treat H. pylori infection
About Novartis Vaccines
Novartis Vaccines, a division of Novartis, is dedicated to the research, development, and commercialization of innovative vaccines aimed at preventing infectious diseases and addressing unmet medical needs globally. With a strong focus on scientific excellence and patient safety, Novartis Vaccines leverages advanced technologies and collaborative partnerships to enhance vaccine efficacy and accessibility. The division is committed to advancing public health through rigorous clinical trials and is driven by a mission to protect lives and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Patients applied
Trial Officials
Novartis Vaccines
Study Chair
Novartis Vaccines
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials